Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 15/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615431 | 0.86 | ERN1 (0.76) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL17615427 | 0.85 | ERN1 (0.74) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL17601914 | 0.85 | ERN1 (1.00) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL17615426 | 0.84 | ERN1 (0.82) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL22882606 | 0.83 | ERN1 (0.71) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL22882598 | 0.82 | ERN1 (0.70) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL22882609 | 0.82 | ERN1 (0.69) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL16197814 | 0.81 | ERN1 (1.00) | ERN1MAOAALDH1A1KDM4EGLA | |
| SCHEMBL16197847 | 0.81 | ERN1 (1.00) | ERN1ALDH1A1KDM4EGLAGAA | |
| SCHEMBL17615432 | 0.81 | ERN1 (0.67) | ERN1MAOAALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | disclosed |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230107770-A1 | METHOD OF ENHANCING IMMUNOTHERAPY USING ER STRESS PATHWAY INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | NATIONAL INSTITUTES OF HEALTH | 2021-01-14 | — | — | US | disclosed |
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, ERN1, SREBF1 | ERN1 2/4885MAOA 4146/4885ALDH1A1 2127/4885 |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, RRP1B, ERN1 | ERN1 3/4885MAOA 3769/4885ALDH1A1 2009/4885 |
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | ERN1 2/4885MAOA 3892/4885ALDH1A1 2686/4885 |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | XBP1, ERN1, ERN2 | ERN1 2/4885MAOA 3892/4885ALDH1A1 2686/4885 |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, DDIT3, ERN1 | ERN1 3/4885MAOA 4317/4885ALDH1A1 2871/4885 |
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, DDIT3, ERN1 | ERN1 3/4885MAOA 4317/4885ALDH1A1 2871/4885 |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | ERN1 2/4885MAOA 3883/4885ALDH1A1 2667/4885 |
| US-20230107770-A1 | METHOD OF ENHANCING IMMUNOTHERAPY USING ER STRESS PATHWAY INHIBITORS | DDIT3, NFATC1, MCL1 | ERN1 57/4885MAOA 4661/4885ALDH1A1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.